A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
-
Narrated by:
-
By:
About this listen
A One‑Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer
Non–muscle invasive bladder cancer is a common, slow-progressing form of bladder cancer that makes up a majority of the roughly half a million new cases diagnosed each year. For decades, doctors have relied on a weakened bacterium called BCG, an intravesical immunotherapy, as a standard treatment for early-stage disease, but it fails in about 30 to 40 percent of patients. EnGene is taking a different approach with detalimogene, an experimental, non-viral gene therapy designed to trigger a powerful but localized immune response right where the cancer lives in the bladder. We spoke with Ron Cooper, CEO of EnGene, about this therapy for non–muscle invasive bladder cancer, how its dual payload is meant to activate both an innate and adaptive immune response in the bladder, and the company’s $130 million financing at the end of 2025.